symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
TNGX,7.2,0.941792,2392462,732513600,0,2.47-13.03,0.68,"Tango Therapeutics, Inc.",USD,0001819133,US87583X1090,87583X109,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.tangotx.com,"Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.",Dr. Barbara L. Weber M.D.,Healthcare,US,110,857 320 4900,100 Binney Street,Cambridge,MA,02142,,0,https://financialmodelingprep.com/image-stock/TNGX.png,2020-09-03,False,False,True,False,False
